Department of Biomorphological and Functional Sciences, University Federico II, Naples, Italy
Institute of Biostructures and Bioimages of the National Research Council (CNR), Naples, Italy
References: Szakacs, G., Paterson, J.K., Ludwig, J.A., Booth-Genthe, C., Gottesman, M.M., Targeting multidrug resistance in cancer (2006) Nat Rev Drug Discov, 5, pp. 219-23
Gottesman, M.M., Fojo, T., Bates, S.E., Multidrug resistance in cancer: Role of ATP-dependent transporters (2002) Nature Reviews Cancer, 2 (1), pp. 48-58
Leonard, G.D., Fojo, T., Bates, S.E., The role of ABC transporters in clinical practice (2003) Oncologist, 8 (5), pp. 411-424. , DOI 10.1634/theoncologist.8-5-411
Danial, N.N., Korsmeyer, S.J., Cell Death: Critical Control Points (2004) Cell, 116 (2), pp. 205-219. , DOI 10.1016/S0092-8674(04)00046-7
Igney, F.H., Krammer, P.H., Death and anti-death: Tumour resistance to apoptosis (2002) Nat Rev Cancer, 2, pp. 277-288
Johnstone, R.W., Ruefli, A.A., Lowe, S.W., Apoptosis: A link between cancer genetics and chemotherapy (2002) Cell, 108, pp. 153-164
Bassik, M.C., Scorrano, L., Oakes, S.A., Pozzan, T., Korsmeyer, S.J., Phosphorylation of BCL-2 regulates ER Ca2+ homeostasis and apoptosis (2004) EMBO Journal, 23 (5), pp. 1207-1216. , DOI 10.1038/sj.emboj.7600104
Kroemer, G., Reed, J.C., Mitochondrial control of cell death (2000) Nat Med, 6, pp. 513-519
Cory, S., Adams, J.M., The BCL2 family: Regulators of the cellular life-or-death switch (2002) Nature Reviews Cancer, 2 (9), pp. 647-656. , DOI 10.1038/nrc883
Sharma, V., Radiopharmaceuticals for assessment of multidrug resistance P-glycoprotein-mediated drug transport activity (2004) Bioconjugate Chemistry, 15 (6), pp. 1464-1474. , DOI 10.1021/bc0498469
Piwnica-Worms, D., Kronauge, J.F., Chiu, M.L., Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence (1990) Circulation, 82, pp. 1826-1838
Delmon-Moingeon, L.I., Piwnica-Worms, D., Van Den Abbeele, A.D., Holman, B.L., Davison, A., Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium- 99m by human carcinoma cell lines in vitro (1990) Cancer Res, 50, pp. 2198-2202
Carvalho, P.A., Chiu, M.L., Kronauge, J.F., Kawamura, M., Jones, A.G., Holman, B.L., Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts (1992) J Nucl Med, 33, pp. 1516-1522
Hendrikse, N.H., Monitoring interactions at ATP-dependent drug efflux pumps (2000) Curr Pharm Des, 6, pp. 1653-1668
Moretti, J.-L., Azaloux, H., Boisseron, D., Kouyoumdjian, J.-C., Vilcoq, J., Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression (1996) European Journal of Nuclear Medicine, 23 (8), pp. 980-986
Kostakoglu, L., Elahi, N., Kiratli, P., Ruacan, S., Sayek, I., Baltali, E., Sungur, A., Bekdik, C.F., Clinical validation of the influence of p-glycoprotein on technetium- 99m-sestamibi uptake in malignant tumors (1997) Journal of Nuclear Medicine, 38 (7), pp. 1003-1008
Del Vecchio, S., Carmiello, A., Potena, M.I., Carriero, M.V., Mainolfi, C., Botti, G., In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients (1997) Eur J Nucl Med, 24, pp. 150-159
Ciarmiello, A., Del Vecchio, S., Silvestro, P., Potena, M.I., Camera, M.V., Thomas, R., Botti, G., Salvatre, M., Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer (1998) Journal of Clinical Oncology, 16 (5), pp. 1677-1683
Sciuto, R., Pasqualoni, R., Bergomi, S., Petrilli, G., Vici, P., Belli, F., Botti, C., Maini, C.L., Prognostic value of99mTc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy (2002) Journal of Nuclear Medicine, 43 (6), pp. 745-751
Takamura, Y., Miyoshi, Y., Taguchi, T., Noguchi, S., Prediction of chemotherapeutic response by Technetium 99m-MIBI scintigraphy in breast carcinoma patients (2001) Cancer, 92 (2), pp. 232-239. , DOI 10.1002/1097-0142(20010715)92:2<232::AID-CNCR1314>
3.0.CO
Mubashar, M., Harrington, K.J., Chaudhary, K.S., Lalani, E.-N., Stamp, G.W., Sinnett, D., Glass, D.M., Peters, A.M., 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer (2002) Journal of Nuclear Medicine, 43 (4), pp. 519-525
Vaidyanathan, G., Zalutsky, M.R., Imaging drug resistance with radiolabeled molecules (2004) Current Pharmaceutical Design, 10 (24), pp. 2965-2979. , DOI 10.2174/1381612043383449
Shih, C.-M., Hsu, W.-H., Huang, W.-T., Wang, J.-J., Ho, S.-T., Kao, A., Usefulness of chest single photon emission computed tomography with technetium-99m methoxyisobutylisonitrile to predict taxol based chemotherapy response in advanced non-small cell lung cancer (2003) Cancer Letters, 199 (1), pp. 99-105. , DOI 10.1016/S0304-3835(03)00335-5
Kawata, K., Kanai, M., Sasada, T., Iwata, S., Yamamoto, N., Takabayashi, A., Usefulness of99mTc-sestamibi scintigraphy in suggesting the therapeutic effect of chemotherapy against gastric cancer (2004) Clinical Cancer Research, 10 (11), pp. 3788-3793. , DOI 10.1158/1078-0432.CCR-1072-3
Chang, C.S., Yang, S.S., Yeh, H.Z., Kao, C.H., Chen, G.H., Tc-99m MIBI liver imaging for hepatocellular carcinoma: Correlation with P-glycoprotein-multidrug-resistance gene expression (2004) Hepatogastroenterology, 51, pp. 211-214
Kostakoglu, L., Noninvasive detection of multidrug resistance in patients with hematological malignancies: Are we there yet? (2002) Clin Lymphoma, 2, pp. 242-248
Fonti, R., Del Vecchio, S., Zannetti, A., De Renzo, A., Catalano, L., Pace, L., Rotoli, B., Salvatore, M., Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma (2004) Cancer Biotherapy and Radiopharmaceuticals, 19 (2), pp. 165-170. , DOI 10.1089/108497804323071931
Pusztai, L., Wagner, P., Ibrahim, N., Rivera, E., Theriault, R., Booser, D., Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma (2005) Cancer, 104, pp. 682-691
Bates, S.E., Bakke, S., Kang, M., Robey, R.W., Zhai, S., Thambi, P., Chen, C., Fojo, T., A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma (2004) Clinical Cancer Research, 10 (14), pp. 4724-4733. , DOI 10.1158/1078-0432.CCR-0829-03
Chen, C.C., Meadows, B., Regis, J., Kalafsky, G., Fojo, T., Carrasquillo, J.A., Bates, S.E., Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi (1997) Clinical Cancer Research, 3 (4), pp. 545-552
Peck, R.A., Hewett, J., Harding, M.W., Wang, Y.-M., Chaturvedi, P.R., Bhatnagar, A., Ziessman, H., Hawkins, M.J., Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin (2001) Journal of Clinical Oncology, 19 (12), pp. 3130-3141
Agrawal, M., Abraham, J., Balis, F.M., Edgerly, M., Stein, W.D., Bates, S., Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576 (2003) Clin Cancer Res, 9, pp. 650-656
Wong, M., Evans, S., Rivory, L.P., Hoskins, J.M., Mann, G.J., Farlow, D., Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer (2005) Clin Pharmacol Ther, 77, pp. 33-42
Hendrikse, N.H., Kuipers, F., Meijer, C., Havinga, R., Bijleveld, C.M., Van Der Graaf, W.T., In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein (2004) Cancer Chemother Pharmacol, 54, pp. 131-138
Aloj, L., Zannetti, A., Caraco, C., Del Vecchio, S., Salvatore, M., Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines (2004) European Journal of Nuclear Medicine and Molecular Imaging, 31 (4), pp. 521-527
Ono, M., Kuwano, M., Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs (2006) Clinical Cancer Research, 12 (24), pp. 7242-7251. , DOI 10.1158/1078-0432.CCR-06-0646
Herbst, R.S., Fukuoka, M., Baselga, J., Gefitinib - A novel targeted approach to treating cancer (2004) Nature Reviews Cancer, 4 (12), pp. 956-965. , DOI 10.1038/nrc1506
Weinstein, I.B., Cancer. Addiction to oncogenes - The Achilles heal of cancer (2002) Science, 297, pp. 63-64
Johnson, B.E., Janne, P.A., Epidermal growth factor receptor mutations in patients with non-small cell lung cancer (2005) Cancer Research, 65 (17), pp. 7525-7529. , DOI 10.1158/0008-5472.CAN-05-1257
Sordella, R., Bell, D.W., Haber, D.A., Settleman, J., Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways (2004) Science, 305 (5687), pp. 1163-1167. , DOI 10.1126/science.1101637
Costa, D.B., Halmos, B., Kumar, A., Schumer, S.T., Huberman, M.S., Boggon, T.J., Tenen, D.G., Kobayashi, S., BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations (2007) PLoS Medicine, 4 (10), pp. 1669-1680. , http://medicine.plosjournals.org/archive/1549-1676/4/10/pdf/10. 1371_journal.pmed.0040315-S.pdf, DOI 10.1371/journal.pmed.0040315
Kuroda, J., Puthalakath, H., Cragg, M.S., Kelly, P.N., Bouillet, P., Huang, D.C.S., Kimura, S., Strasser, A., Bim and Bad mediated imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic (2006) Proceedings of the National Academy of Sciences of the United States of America, 103 (40), pp. 14907-14912. , DOI 10.1073/pnas.0606176103
Zannetti, A., Iommelli, F., Fonti, R., Papaccioli, A., Sommella, J., Lettieri, A., Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-x L modulation of inositol trisphosphate receptor type 3 (2008) Clin Cancer Res, 14, pp. 5209-5219
Orrenius, S., Zhivotovsky, B., Nicotera, P., Regulation of cell death: The calcium-apoptosis link (2003) Nature Reviews Molecular Cell Biology, 4 (7), pp. 552-565. , DOI 10.1038/nrm1150
Oakes, S.A., Scorrano, L., Opferman, J.T., Bassik, M.C., Nishino, M., Pozzan, T., Korsmeyer, S.J., Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum (2005) Proceedings of the National Academy of Sciences of the United States of America, 102 (1), pp. 105-110. , DOI 10.1073/pnas.0408352102
Chen, R., Valencia, I., Zhong, F., McColl, K.S., Roderick, H.L., Bootman, M.D., Berridge, M.J., Distelhorst, C.W., Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release from the ER in response to inositol 1,4,5-trisphosphate (2004) Journal of Cell Biology, 166 (2), pp. 193-203. , DOI 10.1083/jcb.200309146
Gottesman, M. M., Fojo, T., Bates, S. E., Multidrug resistance in cancer: Role of ATP-dependent transporters (2002) Nature Reviews Cancer, 2 (1), pp. 48-58
Leonard, G. D., Fojo, T., Bates, S. E., The role of ABC transporters in clinical practice (2003) Oncologist, 8 (5), pp. 411-424. , DOI 10. 1634/theoncologist. 8-5-411
Danial, N. N., Korsmeyer, S. J., Cell Death: Critical Control Points (2004) Cell, 116 (2), pp. 205-219. , DOI 10. 1016/S0092-8674 (04) 00046-7
Igney, F. H., Krammer, P. H., Death and anti-death: Tumour resistance to apoptosis (2002) Nat Rev Cancer, 2, pp. 277-288
Johnstone, R. W., Ruefli, A. A., Lowe, S. W., Apoptosis: A link between cancer genetics and chemotherapy (2002) Cell, 108, pp. 153-164
Bassik, M. C., Scorrano, L., Oakes, S. A., Pozzan, T., Korsmeyer, S. J., Phosphorylation of BCL-2 regulates ER Ca2+ homeostasis and apoptosis (2004) EMBO Journal, 23 (5), pp. 1207-1216. , DOI 10. 1038/sj. emboj. 7600104
Carvalho, P. A., Chiu, M. L., Kronauge, J. F., Kawamura, M., Jones, A. G., Holman, B. L., Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts (1992) J Nucl Med, 33, pp. 1516-1522
Hendrikse, N. H., Monitoring interactions at ATP-dependent drug efflux pumps (2000) Curr Pharm Des, 6, pp. 1653-1668
Moretti, J. -L., Azaloux, H., Boisseron, D., Kouyoumdjian, J. -C., Vilcoq, J., Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression (1996) European Journal of Nuclear Medicine, 23 (8), pp. 980-986
Shih, C. -M., Hsu, W. -H., Huang, W. -T., Wang, J. -J., Ho, S. -T., Kao, A., Usefulness of chest single photon emission computed tomography with technetium-99m methoxyisobutylisonitrile to predict taxol based chemotherapy response in advanced non-small cell lung cancer (2003) Cancer Letters, 199 (1), pp. 99-105. , DOI 10. 1016/S0304-3835 (03) 00335-5
Chang, C. S., Yang, S. S., Yeh, H. Z., Kao, C. H., Chen, G. H., Tc-99m MIBI liver imaging for hepatocellular carcinoma: Correlation with P-glycoprotein-multidrug-resistance gene expression (2004) Hepatogastroenterology, 51, pp. 211-214
Bates, S. E., Bakke, S., Kang, M., Robey, R. W., Zhai, S., Thambi, P., Chen, C., Fojo, T., A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma (2004) Clinical Cancer Research, 10 (14), pp. 4724-4733. , DOI 10. 1158/1078-0432. CCR-0829-03
Chen, C. C., Meadows, B., Regis, J., Kalafsky, G., Fojo, T., Carrasquillo, J. A., Bates, S. E., Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi (1997) Clinical Cancer Research, 3 (4), pp. 545-552
Peck, R. A., Hewett, J., Harding, M. W., Wang, Y. -M., Chaturvedi, P. R., Bhatnagar, A., Ziessman, H., Hawkins, M. J., Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin (2001) Journal of Clinical Oncology, 19 (12), pp. 3130-3141
Hendrikse, N. H., Kuipers, F., Meijer, C., Havinga, R., Bijleveld, C. M., Van Der Graaf, W. T., In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein (2004) Cancer Chemother Pharmacol, 54, pp. 131-138
Herbst, R. S., Fukuoka, M., Baselga, J., Gefitinib - A novel targeted approach to treating cancer (2004) Nature Reviews Cancer, 4 (12), pp. 956-965. , DOI 10. 1038/nrc1506
Weinstein, I. B., Cancer. Addiction to oncogenes - The Achilles heal of cancer (2002) Science, 297, pp. 63-64
Johnson, B. E., Janne, P. A., Epidermal growth factor receptor mutations in patients with non-small cell lung cancer (2005) Cancer Research, 65 (17), pp. 7525-7529. , DOI 10. 1158/0008-5472. CAN-05-1257
Costa, D. B., Halmos, B., Kumar, A., Schumer, S. T., Huberman, M. S., Boggon, T. J., Tenen, D. G., Kobayashi, S., BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations (2007) PLoS Medicine, 4 (10), pp. 1669-1680. , http: //medicine. plosjournals. org/archive/1549-1676/4/10/pdf/10. 1371_journal. pmed. 0040315-S. pdf, DOI 10. 1371/journal. pmed. 0040315
Oakes, S. A., Scorrano, L., Opferman, J. T., Bassik, M. C., Nishino, M., Pozzan, T., Korsmeyer, S. J., Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum (2005) Proceedings of the National Academy of Sciences of the United States of America, 102 (1), pp. 105-110. , DOI 10. 1073/pnas. 0408352102
Molecular imaging of drug resistance in cancer
Multidrug resistance remains the primary cause of treatment failure in cancer patients. Among the multiple cellular mechanisms underlying the resistant phenotype, the enhanced efflux of anticancer drugs mediated by members of the ATP-binding cassette family of transporters such as P-glycoprotein (Pgp) and the reduced apoptosis due to dysregulation of the process are the most common causes of drug resistance. Here we report the results of our studies on the possibility to detect in vivo and non-invasively malignant tumors that will become resistant to subsequent therapy using single-photon emission tomography and 99mTc-Sestamibi, a tumor-seeking agent currently used in clinical practice. This tracer is a lipophilic cation that accumulates in mitochondria in response to plasma membrane e mitochondrial membrane potentials. In addition, the tracer is subjected to Pgp-mediated outward transport thus mimicking the kinetic behaviour of anticancer drugs in resistant cells. Our studies showed that both the uptake and efflux mechanisms of 99mTc-Sestamibi can be helpful for the non-invasive assessment of drug resistance in cancer. While an enhanced tracer clearance is an index of Pgp-function, an altered pattern of tracer uptake is associated with an impaired apoptosis due to Bcl-2/Bcl-xL overexpression or unopposed action. In conclusion, molecular imaging of drug resistance is suitable and may provide biological information that can improve the efficacy of individual-tailored therapeutic strategies.
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(694 views) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 ViewExport to BibTeXExport to EndNote